# GPT 5.2 Review - Reviewer 1/3 (Parallel)

**Model:** gpt-5.2-2025-12-11
**Paper:** paper.pdf
**Reasoning effort:** medium
**Timestamp:** 2026-01-29T22:20:58.840119
**Review mode:** Parallel (3 independent reviewers)
**Response ID:** resp_0d0bc18ebcd3b90b00697bce7ef0a88190923457611294e66a
**Tokens:** 41439 in / 6254 out
**Response SHA256:** cc9e2a3e76e04e07

---

## Referee Report (Top General-Interest Journal Standard)

### Summary
The paper studies whether state “must-access” PDMP mandates affected state labor market aggregates (log employment, unemployment rate) using LAUS state-year data (March snapshots, 2007–2023) and staggered adoption DiD. The preferred estimator is Callaway & Sant’Anna (2021) with not-yet-treated controls; never-treated controls (KS, MO, NE, SD) are used as a sensitivity check. The headline result is an “informative null.”

The paper is competent and unusually transparent for a policy-evaluation draft, and the core methodology is largely appropriate for staggered adoption. However, for an AER/QJE/JPE/ReStud/Ecta/AEJ:EP bar, the paper is not yet compelling as a *general-interest* contribution, and several identification, measurement, and interpretation issues materially weaken what can be learned from the design. The biggest problem is that the chosen outcomes and aggregation level are very likely too coarse to detect any plausible labor-market channel—something the paper itself essentially concedes via its MDE/dilution discussion—so the “informative null” is much less informative than advertised.

Below I provide a rigorous format check and then focus on (i) inference/methodology, (ii) identification, (iii) positioning in the literature, and (iv) concrete steps to raise the contribution to a top-journal standard.

---

# 1. FORMAT CHECK

**Length**
- The PDF appears to be ~67 pages including appendices/references (page numbers shown through at least p. 67). Excluding references/appendix, the main text looks to be roughly ~35–40 pages (Introduction through Conclusion, plus main tables/figures). **PASS** the ≥25-page expectation.

**References**
- Bibliography includes core PDMP and staggered-DiD references (Callaway & Sant’Anna; Goodman-Bacon; Sun & Abraham; de Chaisemartin & D’Haultfœuille; Borusyak et al.; Rambachan & Roth; Arkhangelsky et al.). Policy literature is present but not fully comprehensive (see Section 4 below). **Borderline** for top journal: key related opioid-policy and labor-market measurement references are missing.

**Prose**
- Major sections are written in paragraphs (Intro pp. 3–5; Institutional Background pp. 5–8; Data pp. 8–12; Empirical Strategy pp. 12–18; Results pp. 19–33; Discussion pp. 34–38; Conclusion p. 38). There are bullet-style enumerations for variables and robustness lists, which is acceptable in Data/Methods. **PASS.**

**Section depth**
- Intro has multiple substantive paragraphs (pp. 3–5). Background and Data are deep. Results section is long with many subsections. Discussion is substantive (pp. 34–38). **PASS.**
- One caveat: some subsections read like technical-report “checklists” (e.g., Robustness pp. 29–34; Appendix narrative), which is fine for a working paper but not for a general-interest journal.

**Figures**
- Figures shown have labeled axes and confidence bands; adoption figure is legible; event studies show axes and bands (Figures 2–6). **PASS.**
- Improvement needed: several plots are visually “flat” with wide bands; readers will ask whether the design has any chance to detect plausible effects. If you keep aggregate outcomes, you need publication-quality figures that *also* communicate power and expected magnitudes (e.g., overlay MDE bands or benchmark effects).

**Tables**
- Tables have real numbers and SEs; no placeholders. **PASS.**
- Minor formatting: be consistent about whether SEs or CIs are shown (main tables mostly SEs; appendix has uniform bands; main text sometimes reports approximate CIs in prose).

---

# 2. STATISTICAL METHODOLOGY (CRITICAL)

### 2a) Standard Errors
- Main coefficients/ATTs are reported with SEs (e.g., Table 3 p. 20; Tables 7–8 pp. 52–54; TWFE Tables 10, etc.). **PASS.**

### 2b) Significance Testing
- p-values are reported in abstract and main text; stars in tables; event-study inference uses uniform bands. **PASS.**

### 2c) Confidence Intervals
- Main text states 95% CI for the headline ATT (e.g., log employment CI approximately [−0.012, 0.019], p. 3–4 / p. 20). Appendix includes uniform CIs for event studies (Table 7). **PASS**, though I recommend putting 95% CIs directly in the main results table for top-journal readability.

### 2d) Sample Sizes
- N is reported (850 state-years) and number of states. **PASS.**  
- However, for cohort/event-time cells, the *effective* N varies sharply at longer horizons; you sometimes note this (Table 6 notes number of cohorts at each horizon). That should be elevated into the main event-study figure notes (not only appendix).

### 2e) Staggered Adoption DiD
- The paper does **not** rely solely on TWFE; it uses Callaway & Sant’Anna (2021) as the primary estimator, discusses TWFE bias, reports Bacon decomposition, and uses not-yet-treated comparisons. **PASS** on the staggered-adoption requirement.

### 2f) RDD
- Not applicable.

**Overall methodology verdict:** **Publishable-in-principle on inference/estimation mechanics.** The paper is not unpublishable on statistical-inference grounds.

**But**: Several methodological choices weaken credibility/interpretation:
1. **Outcome choice + aggregation** likely yields severe attenuation; null results are therefore hard to interpret as policy-irrelevance (more below).
2. **Timing and “March snapshot”** approach is unusual and risks avoidable noise/misclassification.
3. **Not-yet-treated validity** depends on absence of anticipatory behavior *more than one year* and on comparability of soon-to-be-treated states—this needs stronger evidence than currently provided.

---

# 3. IDENTIFICATION STRATEGY

### Credibility of identification
The identification strategy is the usual staggered DiD: compare changes in outcomes around mandate adoption across states. The paper does several things right:
- Explicitly motivates CS (2021) and the thin never-treated issue (pp. 15–17; 29–31).
- Uses an anticipation window of 1 year to address partial exposure from the “full-exposure year” coding (pp. 9–10; 14–15).
- Provides event-study diagnostics with **uniform** confidence bands (pp. 21–25; Fig. 3).
- Includes placebo timing and pre-COVID checks (pp. 31–33; Table 18).

### Key weaknesses / threats
1. **The “informative null” is not actually very informative given plausible effect sizes.**  
   You compute an MDE of ~2.2% for log employment (Table 17 p. 63). That is huge relative to what one would expect from a prescribing policy operating through a small affected share of the workforce. Your own dilution argument (p. 20) implies that even large subgroup effects could yield aggregate impacts far below the MDE. This undercuts the core claim that the null is policy-relevant. In top journals, if the estimand is almost surely too coarse to move, a null is not a result—it is a predictable limitation.

2. **Outcome measurement is a major concern.**
   - Using **March LAUS** (single month) rather than annual averages or monthly panel is not standard and may worsen signal-to-noise (Data section p. 8–9). The argument about “partial-treatment contamination” could be handled more cleanly with monthly data aligned to effective dates (or dropping transition months) rather than restricting to March.
   - LAUS “employment” is not payroll employment; it is a model-based series combining CPS/CES/UI. For state-level aggregates, **QCEW** (UI administrative census of jobs) is typically preferred for employment levels. At a minimum, you need to justify why LAUS is the right employment concept for opioid-policy effects, and show robustness to QCEW/CES.

3. **Treatment definition heterogeneity is substantial, and your 0/1 coding is likely mismeasured.**
   - “Must-access” varies widely (initial-only vs all Rx; schedules covered; exemptions; enforcement; delegate access; EHR integration). Treating all as homogeneous will attenuate effects and possibly create cohort-specific confounding if “strong” mandates are adopted systematically earlier/later.
   - A top-journal version must incorporate policy strength or compliance/enforcement measures (see suggestions below).

4. **Not-yet-treated controls are not automatically “more credible.”**
   - The paper argues the never-treated group is thin and causes pre-trend violations (pp. 21–24; 29–31). That is plausible.
   - But not-yet-treated designs can be biased if adoption is correlated with outcome trends (states that are about to adopt may already be on different trajectories). The event study helps, but given the outcome is extremely smooth/aggregated, pre-trend tests may have low power. HonestDiD helps (pp. 32–33; Fig. 8), but you apply it only to e=0 and only one specification; readers will want broader sensitivity.
   - You should vary the anticipation window (2, 3 years), and show whether estimates are stable.

5. **Confounding from contemporaneous shocks is not convincingly addressed for early cohorts.**
   - You note coal-industry decline for KY/WV (p. 27–28) as a possible confounder for cohort heterogeneity. This is not a footnote issue; it is central because the only “significant” cohort effect is among those states. A stronger design would incorporate region×year shocks, commodity price interactions, or state-specific trends (or explicitly show that including them does not change results).

6. **Spillovers/border effects are hand-waved.**
   - Cross-border substitution for prescriptions and labor markets is plausible. With near-universal adoption it may shrink over time, but early years matter. A border-county analysis (if you move to county data) would address this directly.

### Do conclusions follow from evidence?
- The paper concludes “must-access PDMP mandates… do not produce detectable changes in state-level employment aggregates” (Abstract p. 1; Conclusion p. 38). That is supported.
- The stronger interpretation—“do not produce employment effects over the medium run”—is not warranted given power/aggregation limitations. The correct conclusion is: *no detectable effects on coarse state aggregates; cannot rule out economically meaningful subgroup effects.*

### Limitations discussion
- The paper does discuss dilution, illicit substitution, lags/hysteresis, COVID confounds, and thin control group (pp. 34–38). **PASS**, but the limitations actually undermine the headline framing more than the paper admits.

---

# 4. LITERATURE (Missing references + BibTeX)

You cover the core staggered-DiD methodology and some opioid-policy work. For a top journal, several literatures must be engaged more fully:

## (A) PDMP mandate/policy design and heterogeneity
You need more on PDMP features, strength indices, and mechanisms.

1) **Pardo (2017)** on PDMP characteristics and opioid deaths (commonly cited in PDMP literature).  
```bibtex
@article{Pardo2017,
  author  = {Pardo, Bryce},
  title   = {Do More Robust Prescription Drug Monitoring Programs Reduce Prescription Opioid Overdose?},
  journal = {Addiction},
  year    = {2017},
  volume  = {112},
  number  = {10},
  pages   = {1773--1783}
}
```

2) **Fink et al. (2018)** / CDC-led work on PDMPs and overdose (if you discuss mortality/overdose channels). One option:  
```bibtex
@article{Fink2018,
  author  = {Fink, Dana S. and Schleimer, Julia P. and Sarvet, Aaron and others},
  title   = {Association Between Prescription Drug Monitoring Programs and Nonfatal and Fatal Drug Overdoses},
  journal = {Annals of Internal Medicine},
  year    = {2018},
  volume  = {169},
  number  = {12},
  pages   = {855--863}
}
```
*(Check author list/page numbers for exactness in final manuscript.)*

## (B) Opioid supply restrictions and substitution to illicit markets
You cite Alpert et al. (2018) and Powell et al. (2020), good. But you should incorporate work specifically on policy-induced substitution and unintended consequences.

3) **Mallatt (forthcoming/working)** or **Schnell & Currie (2018)** on opioid supply and harms (if you pivot toward mechanisms). A commonly cited opioid-policy causal paper is:  
```bibtex
@article{SchnellCurrie2018,
  author  = {Schnell, Molly and Currie, Janet},
  title   = {Addressing the Opioid Epidemic: Is There a Role for Physician Education?},
  journal = {American Journal of Health Economics},
  year    = {2018},
  volume  = {4},
  number  = {3},
  pages   = {383--410}
}
```

## (C) Labor-market outcomes measurement at state level
If you claim effects on employment, you must justify the data choice relative to QCEW/CES and classic measurement concerns.

4) **Autor, Dorn, Hanson**-style local labor demand shocks aren’t directly required, but you *do* discuss coal/oil and state shocks; cite something canonical for commodity shocks and local labor markets if you use that story. More importantly, cite inference with few clusters:

5) **Cameron, Gelbach & Miller (2008)** on bootstrap with clustered errors.  
```bibtex
@article{CameronGelbachMiller2008,
  author  = {Cameron, A. Colin and Gelbach, Jonah B. and Miller, Douglas L.},
  title   = {Bootstrap-Based Improvements for Inference with Clustered Errors},
  journal = {Review of Economics and Statistics},
  year    = {2008},
  volume  = {90},
  number  = {3},
  pages   = {414--427}
}
```

6) **MacKinnon & Webb (2017/2018)** wild cluster bootstrap refinements (relevant with 50 clusters and serial correlation).  
```bibtex
@article{MacKinnonWebb2017,
  author  = {MacKinnon, James G. and Webb, Matthew D.},
  title   = {Wild Bootstrap Inference for Wildly Different Cluster Sizes},
  journal = {Journal of Applied Econometrics},
  year    = {2017},
  volume  = {32},
  number  = {2},
  pages   = {233--254}
}
```

## (D) Alternative DiD/event-study practice for policy evaluations
You cite the right recent DiD papers. But if you keep an event-study framing, you should cite the “stacked DiD” approach used widely in AEJ:EP and AER papers:

7) **Cengiz, Dube, Lindner, Zipperer (2019)** (stacked event studies).  
```bibtex
@article{CengizEtAl2019,
  author  = {Cengiz, Doruk and Dube, Arindrajit and Lindner, Attila and Zipperer, Ben},
  title   = {The Effect of Minimum Wages on Low-Wage Jobs},
  journal = {Quarterly Journal of Economics},
  year    = {2019},
  volume  = {134},
  number  = {3},
  pages   = {1405--1454}
}
```

**Why these matter:** Right now, the paper’s contribution is “CS DiD + long panel + null on aggregates.” To clear a top-journal bar, you need either (i) much sharper outcomes/data/mechanisms, or (ii) a methodological contribution about thin control groups with near-universal adoption. If you want (ii), you must engage much more with the growing literature on designs with few/zero never-treated units (synthetic DiD variants, augmented SCM, interactive fixed effects, etc.).

---

# 5. WRITING QUALITY (CRITICAL)

### 5a) Prose vs bullets
- Main sections are paragraph-based. Bullets mainly appear where acceptable (variable definitions, robustness enumerations). **PASS.**

### 5b) Narrative flow
- The introduction (pp. 3–5) motivates an important question and cleanly distinguishes “opioids harm labor markets” from “opioid policies improve labor markets.” That’s good.
- However, the narrative arc becomes *method-heavy* and reads like a careful technical report rather than a general-interest paper. The best AEJ:EP/AER papers keep the “economic question” in the foreground even while being methodologically modern.

### 5c) Sentence quality
- Generally clear and grammatically strong. But there is repetition (“informative null,” “thin control group,” “not-yet-treated preferred”) and too much hedging/qualifier stacking in Results/Robustness.

### 5d) Accessibility
- Technical choices (CS estimator, uniform bands, HonestDiD) are explained reasonably well (pp. 12–18; 32–33).
- Magnitudes are contextualized somewhat (MDE discussion p. 20; dilution p. 35), but this cuts against your own framing: the paper admits it cannot detect plausible effects, yet still markets the null as policy-informative.

### 5e) Figures/Tables
- Labels and notes are generally adequate.  
- But for publication quality: figures should be redesigned to be interpretable in black-and-white print; fonts are small; and event-study plots should visually communicate changing sample composition over event time (e.g., annotate number of cohorts/states contributing at each e).

**Writing verdict:** Readable, but not yet at the “beautifully written general-interest” level. The main barrier is not grammar; it’s *framing and interpretive discipline*.

---

# 6. CONSTRUCTIVE SUGGESTIONS (How to make it top-journal)

### A. Upgrade outcomes/data so the estimand matches the mechanism
If the mechanism is “reduced opioid misuse → improved labor supply/productivity,” state-level total employment is the bluntest possible outcome. Stronger options:

1) **Use QCEW employment (and wages) by county/industry**  
   - Opioid impacts are concentrated in certain sectors (construction, mining, manufacturing) and places. County-by-quarter panels can support richer designs and more power.
   - With county data you can do border analyses and exploit within-state heterogeneity.

2) **Use CPS microdata (or ACS) to estimate EPOP, LFPR, disability, hours**  
   - You already align to March for CPS ASEC, but you don’t use CPS outcomes. For labor supply, EPOP/LFPR is conceptually closer than LAUS “employment level.”
   - Heterogeneity by age/education/sex is crucial. The mandate should most plausibly affect prime-age workers with pain/injury exposure.

3) **Look at disability insurance (SSDI) applications/receipt**  
   - Krueger (2017) and Autor & Duggan (2003) motivate a disability channel. If PDMP mandates matter, SSDI flows might be more sensitive than total employment.

### B. Strengthen treatment measurement (policy heterogeneity)
Create (or adopt) a **PDMP mandate strength index**:
- all-schedule vs schedule-II-only
- initial-only vs all prescriptions
- required frequency of re-check
- enforcement/penalties
- delegate access
- EHR integration / real-time reporting
Then estimate dose-response (continuous treatment) and event studies by strength. This is a clear way to turn a likely-null average effect into a more informative set of results.

### C. Address adoption endogeneity more directly
Even with CS DiD, adoption timing can correlate with trends. Add:
- **Alternative anticipation windows** (2–3 years) and show stability.
- **State-specific linear trends** and/or **region×year fixed effects** as robustness (with appropriate caution; don’t over-control mechanically).
- **Pre-period matching/weighting**: show that reweighting treated and controls to match pre-trends yields the same null.

### D. Reframe the contribution honestly
If the core finding is “no detectable aggregate effects,” the paper should either:
1) become a methodological paper about evaluation with near-universal adoption and thin controls, **or**
2) become a substantive opioid/labor paper by moving to outcomes/data where effects are plausibly detectable.

Right now it sits in between: it is not methodologically novel enough for Ecta/ReStud, and not substantively sharp enough for AER/QJE/JPE/AEJ:EP.

### E. Clarify internal inconsistencies and tighten presentation
- Fix inconsistent citations/years: Table 2 notes “Horwitz et al. (2018)” while references list Horwitz et al. (2021). This is a credibility issue in policy coding.
- Provide a concise “paper map” and a one-paragraph “what you learn that we didn’t know” statement on p. 4–5.
- Put the **preferred estimand and comparison group choice** front-and-center, but also acknowledge the not-yet-treated identifying assumption costs (anticipation/adoption endogeneity), not only benefits.

---

# 7. OVERALL ASSESSMENT

### Key strengths
- Correctly uses modern staggered DiD tools; clear discussion of TWFE pitfalls (pp. 12–14).
- Transparent about thin never-treated controls and shows diagnostics (pp. 21–24; 29–31).
- Event studies with uniform bands and bootstrap inference are above the norm for applied work.
- Sensitivity analysis (HonestDiD) is a good step (pp. 32–33), though too narrow in scope.

### Critical weaknesses (why it would not clear a top-journal bar now)
1. **Mismatch between mechanism and outcome aggregation**: state total employment is too coarse; null is not very informative given MDE and dilution.
2. **Treatment mismeasurement/heterogeneity**: a 0/1 must-access indicator across very different mandates is unlikely to identify meaningful variation.
3. **Control-group argument is incomplete**: not-yet-treated may fix thin-controls but raises adoption-endogeneity/anticipation concerns that are not fully probed.
4. **Contribution positioning**: too close to “Kaestner & Ziedan (2023) but with LAUS + CS DiD.” The incremental insight is limited unless outcomes/mechanisms are sharpened.

### Specific high-priority revisions
- Replace/augment LAUS with QCEW/CPS outcomes; add heterogeneity by population most affected.
- Build a mandate-strength measure; estimate dose-response.
- Expand sensitivity: anticipation windows; adoption-endogeneity probes; pre-trend matching.
- Tighten narrative: either make it a methods paper about thin controls, or a substantive opioid-labor paper with sharper outcomes.

---

DECISION: REJECT AND RESUBMIT